207 related articles for article (PubMed ID: 9755839)
1. Clinical significance of serum soluble Fas ligand in patients with acute self-limited and fulminant hepatitis.
Shiota G; Oyama K; Noguchi N; Takano Y; Kitaoka S; Kawasaki H
Res Commun Mol Pathol Pharmacol; 1998 Jul; 101(1):3-12. PubMed ID: 9755839
[TBL] [Abstract][Full Text] [Related]
2. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure.
Nakae H; Narita K; Endo S
J Crit Care; 2001 Jun; 16(2):59-63. PubMed ID: 11481600
[TBL] [Abstract][Full Text] [Related]
3. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure.
Ryo K; Kamogawa Y; Ikeda I; Yamauchi K; Yonehara S; Nagata S; Hayashi N
Am J Gastroenterol; 2000 Aug; 95(8):2047-55. PubMed ID: 10950056
[TBL] [Abstract][Full Text] [Related]
4. Significance of soluble TNF receptor-I in acute-type fulminant hepatitis.
Tokushige K; Yamaguchi N; Ikeda I; Hashimoto E; Yamauchi K; Hayashi N
Am J Gastroenterol; 2000 Aug; 95(8):2040-6. PubMed ID: 10950055
[TBL] [Abstract][Full Text] [Related]
5. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
[TBL] [Abstract][Full Text] [Related]
6. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K
Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553
[TBL] [Abstract][Full Text] [Related]
7. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
8. Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand.
Matsuno H; Yudoh K; Watanabe Y; Nakazawa F; Aono H; Kimura T
J Rheumatol; 2001 Jan; 28(1):22-8. PubMed ID: 11196534
[TBL] [Abstract][Full Text] [Related]
9. Significance of Fas and Fas ligand in tuberculous lymphadenitis.
Mustafa T; Mogga SJ; Mfinanga SG; Mørkve O; Sviland L
Immunology; 2005 Feb; 114(2):255-62. PubMed ID: 15667570
[TBL] [Abstract][Full Text] [Related]
10. Pleural effusion and serum soluble fas-ligand levels are elevated in different clinical conditions.
Wang PS; Chen YM; Hsieh YL; Yu CF; Tsai CM; Perng RP
Lung; 2002; 180(1):25-32. PubMed ID: 12105754
[TBL] [Abstract][Full Text] [Related]
11. Soluble Fas and soluble Fas L levels in patients with acute pancreatitis.
Endo S; Inoue Y; Fujino Y; Yamada Y; Sato N; Wakabayashi G; Sakamoto T; Ishikura H; Tanaka T; Inada K; Sato S
Res Commun Mol Pathol Pharmacol; 2000; 108(3-4):179-86. PubMed ID: 11913710
[TBL] [Abstract][Full Text] [Related]
12. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus.
Song le H; Binh VQ; Duy DN; Bock TC; Kremsner PG; Luty AJ; Mavoungou E
J Med Virol; 2004 Jun; 73(2):244-9. PubMed ID: 15122799
[TBL] [Abstract][Full Text] [Related]
13. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
Raghuraman S; Abraham P; Daniel HD; Ramakrishna BS; Sridharan G
J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
[TBL] [Abstract][Full Text] [Related]
14. Soluble Fas ligand expression in the ocular fluids of uveitis patients.
Sotozono C; Sano Y; Suzuki T; Tada R; Ikeda T; Nagata S; Kinoshita S
Curr Eye Res; 2000 Jan; 20(1):54-7. PubMed ID: 10611715
[TBL] [Abstract][Full Text] [Related]
15. Levels of the human hepatocyte growth factor in serum of patients with various liver diseases determined by an enzyme-linked immunosorbent assay.
Tsubouchi H; Niitani Y; Hirono S; Nakayama H; Gohda E; Arakaki N; Sakiyama O; Takahashi K; Kimoto M; Kawakami S
Hepatology; 1991 Jan; 13(1):1-5. PubMed ID: 1824837
[TBL] [Abstract][Full Text] [Related]
16. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors.
Kondera-Anasz Z; Mielczarek-Palacz A; Sikora J
Apoptosis; 2005 Oct; 10(5):1143-9. PubMed ID: 16151647
[TBL] [Abstract][Full Text] [Related]
17. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease.
Kanda Y; Tanaka Y; Shirakawa K; Yatomi T; Nakamura N; Kami M; Saito T; Izutsu K; Asai T; Yuji K; Ogawa S; Honda H; Mitani K; Chiba S; Yazaki Y; Hirai H
Bone Marrow Transplant; 1998 Oct; 22(8):751-4. PubMed ID: 9827971
[TBL] [Abstract][Full Text] [Related]
18. Clinical importance of circulating and cellular expression levels of Fas and Fas ligand in pediatric patients with lymphoproliferative malignancies.
Hazar V; Berber Z; Pestereli E; Coskun M; Yesilipek A; Karpuzoglu G; Yegin O
Pediatr Hematol Oncol; 2005; 22(3):247-56. PubMed ID: 16020109
[TBL] [Abstract][Full Text] [Related]
19. FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
Nadal C; Maurel J; Gallego R; Castells A; Longarón R; Marmol M; Sanz S; Molina R; Martin-Richard M; Gascón P
Clin Cancer Res; 2005 Jul; 11(13):4770-4. PubMed ID: 16000573
[TBL] [Abstract][Full Text] [Related]
20. Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy.
Péron JM; Bureau C; Poirson H; Mansuy JM; Alric L; Selves J; Dupuis E; Izopet J; Vinel JP
J Viral Hepat; 2007 May; 14(5):298-303. PubMed ID: 17439518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
